Clinical Trial Update: Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating the safety and efficacy of daptomycin for complicated skin and skin-structure infections (soft tissue infections).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Skin and Skin Structure Infections
• Soft Tissue Infections

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Soft Tissue Infections | Phase 2 | Status: COMPLETED